CA
AKBA icon

Clearstead Advisors’s Akebia Therapeutics AKBA Stock Holding History

Clearstead Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773 Buy
+678
New +$807 ﹤0.01% 2786
2025
Q4 		– Sell
-838
Closed -$2.29K – 2751
2025
Q3 		$2.29K Hold
838
– – ﹤0.01% 2412
2025
Q2 		$3.05K Buy
+838
New +$2.3K ﹤0.01% 2237

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Clearstead Advisors's AKBA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 678 shares worth $773. The stake represents ﹤0.01% of the portfolio and ranks #2786 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in AKBA as recently as Q3 2025.

Clearstead Advisors first reported a position in AKBA in Q2 2025 and has held it in 3 quarters since. The position peaked at $3.05K in Q2 2025. 60 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Clearstead Advisors held 678 shares of Akebia Therapeutics worth $773 as of Q2 2026.
  • Akebia Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2786 holding.
  • Clearstead Advisors first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Akebia Therapeutics position peaked at $3.05K in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.